VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2004 participants.
Also called NCT01528254
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 2,004 participants
- Sponsor
- Registry
-
NCT01528254 -
2011-003712-23
-
- Other papers using this trial's data
- Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Argentina, Australia, Austria, Brazil, Bulgaria, Colombia, Czechia, Dominican Republic, Estonia, Finland, Germany, Guatemala, Hong Kong SAR China, Hungary, India, Israel, Italy, Latvia, Lithuania, Malaysia, Mexico, Norway, Panama, Peru, Philippines, Poland, Romania, Russia, Slovakia, South Africa, South Korea, Spain, Taiwan, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT01528254. Randomized; quadruple masking; primary purpose treatment. Start 2012-03-30 (actual); primary completion 2019-04-04 (actual). Results posted on 2020-04-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Placebo of vildagliptin
- Intervention (Drug)
- vildagliptin
- Intervention (Drug)
- Metformin
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct01528254- Content hash
fe48c01e17e844997e45e19b968746f7a476bc35aee99074682e211c53a92913